Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled After the FDA Approval Date of Anagrelide
American Journal of Hematology - United States
doi 10.1002/ajh.25294
Full Text
Open PDFAbstract
Available in full text
Categories
Date
October 17, 2018
Authors
Publisher
Wiley